RedHill Biopharma RDHL
NASDAQ RDHL
$0.48 -0.03 (-5.38%)
As of: Oct 21, 2026 · 11:38 AM EDT

RedHill Biopharma (RDHL) Non-Current Debt (2020 - 2022)

Updated

RedHill Biopharma's Non-Current Debt was $113.86 million in the quarter ended Sep 30, 2022, up 36.3% from $83.52 million a year earlier.

Analysis

RedHill Biopharma (RDHL) Non-Current Debt (2020 - 2022) Analysis & Trends

As of Dec 31, 2021, Non-Current Debt at RedHill Biopharma came in at $83.62 million, up 2.7% from the prior year.

  • In earlier years, Non-Current Debt was $81.39 million in the year ended Dec 31, 2020.
  • The figure for the quarter ended Sep 30, 2022 marks the highest quarterly Non-Current Debt in data going back to the quarter ended Mar 31, 2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Eli Lilly 1,130.22 Bn 1,098.81 Bn 19.71 Bn 47.86 Bn
2 Johnson & Johnson 613.62 Bn 532.15 Bn 17.26 Bn 37.34 Bn
3 AbbVie 501.46 Bn 474.57 Bn 12.70 Bn 62.48 Bn
4 Merck 366.84 Bn 321.22 Bn 12.21 Bn 51.08 Bn
5 Novartis Ag 297.85 Bn 261.84 Bn 11.24 Bn 1.96 Bn
6 Astrazeneca 261.66 Bn 235.34 Bn 12.86 Bn 23.68 Bn
7 Amgen 235.39 Bn 190.79 Bn 7.24 Bn 51.86 Bn
8 Gilead Sciences 190.66 Bn 164.86 Bn 6.22 Bn 23.83 Bn
9 Pfizer 169.57 Bn 116.22 Bn 10.94 Bn 60.50 Bn
10 RedHill Biopharma 1.52 Mn -15.10 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2022 113.86 Mn
Mar 31, 2022 86.40 Mn
Dec 31, 2021 83.62 Mn
Sep 30, 2021 83.52 Mn
Jun 30, 2021 83.16 Mn
Mar 31, 2021 82.52 Mn
Dec 31, 2020 81.39 Mn
Sep 30, 2020 80.27 Mn
Jun 30, 2020 79.19 Mn
Mar 31, 2020 78.17 Mn
API Access

RedHill Biopharma Non-Current Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-debt&ticker=RDHL&period=max&api_key=YOUR_API_KEY